title: Adalimumab-Receiving Ulcerative Colitis Patient Suffered Latent Tuberculosis Reactivation Despite Correct Chemoprophylaxis and was Successfully Treated while on Anti-Tumour Necrosis Factor Therapy.
authors.affiliation: Department of Gastroenterology and Hepatology, Puerta de Hierro University Hospital, Madrid, Spain.
authors.forename: Belén
authors.initials: B
authors.lastname: Agudo
authors.affiliation: Department of Pneumology, Puerta de Hierro University Hospital, Madrid, Spain.
authors.forename: Gema
authors.initials: G
authors.lastname: Díaz
authors.affiliation: Department of Gastroenterology and Hepatology, Puerta de Hierro University Hospital, Madrid, Spain ygonzalezlama@telefonica.net.
authors.forename: Yago
authors.initials: Y
authors.lastname: González-Lama
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D055985:Latent Tuberculosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000995:Antitubercular Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D007538:Isoniazid